Today the European Medicines Agency (EMA) has approved the drug Alemtuzumab, trade name Lemtrada, and formerly known as Campath, for the treatment of multiple sclerosis. Alemtuzumab’s manufacturer is awaiting a decision from the FDA regarding approval in the United States. Alemtuzumab is a monoclonal antibody that has also been used in the treatment of various immune system cancers, like lymphoma and leukemia. Alemtuzumab appears to a powerful drug in the treatment of relapsing-remitting MS, however, a number of safety concerns exist. Patients taking this drug have a high incidence of the development of other autoimmune conditions, like thyroid disease as well as a potentially life threatening condition of low platelets (a blood cell important for clotting). While routine blood tests can monitor for these conditions, the use of this drug will likely be reserved for aggressive cases or those that are refractory to other treatments.